CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Charles River Laboratories provides preclinical drug discovery, development, and safety testing services to pharmaceutical, biotechnology, and medical device companies. The company operates across the drug development pipeline, offering services that range from early-stage compound screening through regulatory toxicology and pathology studies required before human trials. Its work encompasses both traditional small-molecule drugs and emerging modalities including biotherapeutics, oligonucleotides, and antibody-drug conjugates.

The company operates three primary business segments. Research Models and Services produces laboratory rodents and genetically engineered animal models, along with associated research support services and animal diagnostic testing. Discovery and Safety Assessment delivers in vitro and in vivo preclinical testing, including toxicology, pharmacokinetics, and safety pharmacology studies, as well as vivarium space for client operations. Manufacturing Solutions provides quality control testing for pharmaceuticals and consumer products, contract development and manufacturing services, and specialized testing for biologic therapeutics.

Charles River employs approximately 18,300 people and maintains operations across North America, Europe, Asia Pacific, and other international markets. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.